Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, ...

After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the ...

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean ...

The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...

Amid the pharma industry's breakneck onshoring push this past year, North Carolina has been a major beneficiary as investment announcements rolled in from the likes of ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...

When Ali Sullivan enrolled at Indiana University, she thought she wanted to become a speech pathologist. Midway through her ...